Peptides›Cognitive›Selank

Selank

/ Synthetic heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro (stabilized analog of tuftsin)

TIER 3 · PreclinicalN = 0 · TESTING PENDINGLAST REVIEW 2026·04·20

—

Pass rate

Samples

Suppliers

Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity

Primary sequence— sequence not captured —

MW · —CLASS · Synthetic heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro (stabilized analog of tuftsin)CATEGORY · Cognitive

Registered and used clinically in Russia for generalized anxiety disorder. No Western RCTs. Claimed anxiolytic efficacy without benzodiazepine-associated liabilities has not been validated in Western trials.

§ B · Mechanism of action

Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro), a stabilized analog of the immunomodulatory tetrapeptide tuftsin. Proposed anxiolytic mechanisms include modulation of GABAergic transmission, enkephalinase inhibition (prolonging endogenous enkephalin action), and modulation of BDNF and serotonin turnover. As with Semax, the bulk of mechanism work is Russian.

§ C · Human clinical evidence

Limited. Registered and used clinically in Russia for generalized anxiety disorder. No Western RCTs. No ClinicalTrials.gov entries from Western centers.

§ D · Primary literature

PubMed17593862Medvedev VE et al. — Efficacy and safety of Selank in the treatment of anxiety disorders and neurasthenia · Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova · human-phase-2Russian-published trial reported anxiolytic effect comparable to medazepam in patients with generalized anxiety disorder and neurasthenia, without benzodiazepine-associated withdrawal phenomena.Limitations: Russian-language publication with limited methodology detail in English abstract; not independently replicated in Western trials.2007

§ F · Safety signal

Russian literature reports absence of sedation, amnesia, withdrawal, or dependence — distinguishing claims versus benzodiazepines. Independent safety validation is lacking.

§ H · Regulatory status

Regulatory status

FDA status:: Not FDA-approved

§ I · Notable gaps and controversies

Russian-origin literature dominates. Claimed anxiolytic efficacy without benzodiazepine liabilities is a strong claim not yet validated by Western trials.